Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck.

Margalit DN, Haddad RI, Tishler RB, Chau NG, Schoenfeld JD, Bakst RL, Misiukiewicz KJ, Gupta V, Posner M, Hanna GJ, Mahmood U, Rawal B, Catalano PJ, Rath L, Bacay A, McHugh P, Rabinowits G.

Int J Radiat Oncol Biol Phys. 2019 May 11. pii: S0360-3016(19)30698-4. doi: 10.1016/j.ijrobp.2019.04.034. [Epub ahead of print]

PMID:
31082494
2.

Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.

Kacew AJ, Harris EJ, Lorch JH, Haddad RI, Chau NG, Rabinowits G, LeBoeuf NR, Schmults CD, Thakuria M, MacConaill LE, Hanna GJ.

Eur J Cancer. 2019 May;113:1-9. doi: 10.1016/j.ejca.2019.03.004. Epub 2019 Apr 4.

PMID:
30954880
3.

IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing.

LaVigne AW, Margalit DN, Rawal B, Puzanov M, Annino DJ, Goguen LA, Sher DJ, Schoenfeld JD, Chau NG, Lorch JH, Rabinowits G, Haddad RI, Tishler RB.

Head Neck. 2019 Apr;41(4):959-966. doi: 10.1002/hed.25531. Epub 2019 Jan 8.

PMID:
30620435
4.

Acquired perforating calcific collagenosis in a drug addict with rhabdomyolysis and transient hypercalcemia.

Wang FY, Ng CY, Wu J, Kuo KL, Chang YY, Kuo TT.

J Cutan Pathol. 2019 Jan;46(1):84-87. doi: 10.1111/cup.13371. Epub 2018 Nov 12.

PMID:
30311260
5.

Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.

Sridharan V, Rahman RM, Huang RY, Chau NG, Lorch JH, Uppaluri R, Haddad RI, Hanna GJ, Schoenfeld JD.

Oral Oncol. 2018 Oct;85:29-34. doi: 10.1016/j.oraloncology.2018.08.005. Epub 2018 Aug 17.

PMID:
30220316
6.

Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial.

Colevas AD, Bahleda R, Braiteh F, Balmanoukian A, Brana I, Chau NG, Sarkar I, Molinero L, Grossman W, Kabbinavar F, Fassò M, O'Hear C, Powderly J.

Ann Oncol. 2018 Nov 1;29(11):2247-2253. doi: 10.1093/annonc/mdy411.

PMID:
30219915
7.

Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma.

Mandelbaum J, Shestopalov IA, Henderson RE, Chau NG, Knoechel B, Wick MJ, Zon LI.

J Exp Med. 2018 Oct 1;215(10):2673-2685. doi: 10.1084/jem.20180939. Epub 2018 Sep 12.

8.

Dermatoscopy of Common Lesions in Pediatric Dermatology.

Micali G, Verzì AE, Quattrocchi E, Ng CY, Lacarrubba F.

Dermatol Clin. 2018 Oct;36(4):463-472. doi: 10.1016/j.det.2018.05.012. Epub 2018 Aug 16. Review.

PMID:
30201155
9.

Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer.

Hanna GJ, Kacew A, Chau NG, Shivdasani P, Lorch JH, Uppaluri R, Haddad RI, MacConaill LE.

JCI Insight. 2018 Sep 6;3(17). pii: 122799. doi: 10.1172/jci.insight.122799. eCollection 2018 Sep 6.

10.

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM.

Nat Genet. 2018 Sep;50(9):1271-1281. doi: 10.1038/s41588-018-0200-2. Epub 2018 Aug 27.

11.

Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.

Schoenfeld JD, Gjini E, Rodig SJ, Tishler RB, Rawal B, Catalano PJ, Uppaluri R, Haddad RI, Hanna GJ, Chau NG, Rabinowits G, Lorch J, Jo VY, Krane JF, Goguen LA, Annino DJ, Abdelrahman S, Lipschitz M, Margalit DN.

Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):137-145. doi: 10.1016/j.ijrobp.2018.05.002. Epub 2018 Jun 29.

PMID:
29960819
12.

Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Chen CB, Wu MY, Ng CY, Lu CW, Wu J, Kao PH, Yang CK, Peng MT, Huang CY, Chang WC, Hui RC, Yang CH, Yang SF, Chung WH, Su SC.

Cancer Manag Res. 2018 May 17;10:1259-1273. doi: 10.2147/CMAR.S163391. eCollection 2018. Review.

13.

Using weighted regression model for estimating cohort effect in age-period contingency table data.

Tzeng IS, Ng CY, Chen JY, Chen LS, Wu CC.

Oncotarget. 2018 Apr 13;9(28):19826-19835. doi: 10.18632/oncotarget.24868. eCollection 2018 Apr 13.

14.

Psychosocial distress and the preferred method of delivery of mind-body interventions among patients with head-and-neck cancer.

Budhrani-Shani P, Chau NG, Berry DL.

Patient Relat Outcome Meas. 2018 Apr 3;9:129-136. doi: 10.2147/PROM.S149978. eCollection 2018.

15.

Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Ng CY, Chen CB, Wu MY, Wu J, Yang CH, Hui RC, Chang YC, Lu CW.

J Immunol Res. 2018 Jan 17;2018:5376476. doi: 10.1155/2018/5376476. eCollection 2018. Review.

16.

Phytochemicals in Skin Cancer Prevention and Treatment: An Updated Review.

Ng CY, Yen H, Hsiao HY, Su SC.

Int J Mol Sci. 2018 Mar 22;19(4). pii: E941. doi: 10.3390/ijms19040941. Review.

17.

Frameshift events predict anti-PD-1/L1 response in head and neck cancer.

Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, MacConaill LE, Haddad RI.

JCI Insight. 2018 Feb 22;3(4). pii: 98811. doi: 10.1172/jci.insight.98811. eCollection 2018 Feb 22.

18.

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.

Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD Jr, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH.

Clin Cancer Res. 2018 Apr 1;24(7):1546-1553. doi: 10.1158/1078-0432.CCR-17-2297. Epub 2018 Jan 4.

19.

Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab).

Ng CY, Tzeng IS, Liu SH, Chang YC, Huang YH.

J Dermatol. 2018 Mar;45(3):309-313. doi: 10.1111/1346-8138.14079. Epub 2017 Oct 5. Retraction in: J Dermatol. 2018 Aug;45(8):1026.

PMID:
28980716
20.

Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy.

Margalit DN, Schoenfeld JD, Rawal B, Haddad RI, Catalano PJ, Goguen LA, Chau NG, Rabinowits G, Lorch JH, Annino DJ, Tishler RB.

Oral Oncol. 2017 Oct;73:160-165. doi: 10.1016/j.oraloncology.2017.08.012. Epub 2017 Sep 8.

PMID:
28939070
21.

Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma.

Sajed DP, Faquin WC, Carey C, Severson EA, H Afrogheh A, A Johnson C, Blacklow SC, Chau NG, Lin DT, Krane JF, Jo VY, Garcia JJ, Sholl LM, Aster JC.

Am J Surg Pathol. 2017 Nov;41(11):1473-1482. doi: 10.1097/PAS.0000000000000945.

22.

Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma.

Hanna GJ, Sridharan V, Margalit DN, La Follette SK, Chau NG, Rabinowits G, Lorch JH, Haddad RI, Tishler RB, Anderson KS, Schoenfeld JD.

Cancer Biomark. 2017;19(2):129-136. doi: 10.3233/CBM-160071.

PMID:
28387659
23.

Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck.

Hanna GJ, Liu H, Jones RE, Bacay AF, Lizotte PH, Ivanova EV, Bittinger MA, Cavanaugh ME, Rode AJ, Schoenfeld JD, Chau NG, Haddad RI, Lorch JH, Wong KK, Uppaluri R, Hammerman PS.

Oral Oncol. 2017 Apr;67:61-69. doi: 10.1016/j.oraloncology.2017.02.005. Epub 2017 Feb 14.

PMID:
28351582
24.

Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.

Song JS, Tawa M, Chau NG, Kupper TS, LeBoeuf NR.

BMC Cancer. 2017 Mar 16;17(1):200. doi: 10.1186/s12885-017-3194-8.

25.

Doubly Dangerous: Extranodal NK/T-Cell Lymphoma.

Yang SJ, Ng CY, Yang CH, Lu PH.

Am J Med. 2017 Jun;130(6):669-672. doi: 10.1016/j.amjmed.2017.02.003. Epub 2017 Feb 20. No abstract available.

PMID:
28223064
26.

Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations.

Li YY, Chung GT, Lui VW, To KF, Ma BB, Chow C, Woo JK, Yip KY, Seo J, Hui EP, Mak MK, Rusan M, Chau NG, Or YY, Law MH, Law PP, Liu ZW, Ngan HL, Hau PM, Verhoeft KR, Poon PH, Yoo SK, Shin JY, Lee SD, Lun SW, Jia L, Chan AW, Chan JY, Lai PB, Fung CY, Hung ST, Wang L, Chang AM, Chiosea SI, Hedberg ML, Tsao SW, van Hasselt AC, Chan AT, Grandis JR, Hammerman PS, Lo KW.

Nat Commun. 2017 Jan 18;8:14121. doi: 10.1038/ncomms14121.

27.

Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma.

Jo VY, Chau NG, Hornick JL, Krane JF, Sholl LM.

Mod Pathol. 2017 May;30(5):650-659. doi: 10.1038/modpathol.2016.239. Epub 2017 Jan 13.

28.

Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.

Abramson VG, Supko JG, Ballinger T, Cleary JM, Hilton JF, Tolaney SM, Chau NG, Cho DC, Pearlberg J, Lager J, Shapiro GI, Arteaga CL.

Clin Cancer Res. 2017 Jul 15;23(14):3520-3528. doi: 10.1158/1078-0432.CCR-16-1764. Epub 2016 Dec 28.

29.

Cutaneous Exophiala oligosperma Infection in a Patient with Bullous Pemphigoid with a Review of the Literature.

Ng CY, de Hoog S, Li HE, Lee YY, Chen CB, Sun PL.

Mycopathologia. 2017 Jun;182(5-6):539-547. doi: 10.1007/s11046-016-0104-6. Epub 2016 Dec 26. Review.

PMID:
28025758
30.

Evaluation of Laser-Assisted Trans-Nail Drug Delivery with Optical Coherence Tomography.

Tsai MT, Tsai TY, Shen SC, Ng CY, Lee YJ, Lee JD, Yang CH.

Sensors (Basel). 2016 Dec 12;16(12). pii: E2111.

31.

Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians.

Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, Sukasem C, Hsu CN, Su SC, Chang WC, Hui RC, Chu CY, Chen YJ, Wu CY, Hsu CK, Chiu TM, Sun PL, Lee HE, Yang CY, Kao PH, Yang CH, Ho HC, Lin JY, Chang YC, Chen MJ, Lu CW, Ng CY, Kuo KL, Lin CY, Yang CS, Chen DP, Chang PY, Wu TL, Lin YJ, Weng YC, Kuo TT, Hung SI, Chung WH; Taiwan Severe Cutaneous Adverse Reaction Consortium.

Neurology. 2017 Jan 3;88(1):78-86. doi: 10.1212/WNL.0000000000003453. Epub 2016 Dec 2.

PMID:
27913699
32.

Highlights in Head and Neck Cancer.

Chau NG, Tishler RB, Haddad RI.

JAMA Oncol. 2017 Apr 1;3(4):441-442. doi: 10.1001/jamaoncol.2016.3648. No abstract available.

PMID:
27893016
33.

Massachusetts Healthcare Reform and Trends in Emergent Colon Resection.

Eskander MF, Bliss LA, McCarthy EP, de Geus SW, Chau Ng S, Nagle D, Rodrigue JR, Tseng JF.

Dis Colon Rectum. 2016 Nov;59(11):1063-1072.

PMID:
27749482
34.

Antiangiogenic agents in head and neck squamous cell carcinoma: Tired of going solo.

Chau NG, Haddad RI.

Cancer. 2016 Dec 1;122(23):3592-3595. doi: 10.1002/cncr.30352. Epub 2016 Sep 20. No abstract available.

35.

Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.

Chau NG, Hurwitz S, Mitchell CM, Aserlind A, Grunfeld N, Kaplan L, Hsi P, Bauer DE, Lathan CS, Rodriguez-Galindo C, Tishler RB, Haddad RI, Sallan SE, Bradner JE, French CA.

Cancer. 2016 Dec 1;122(23):3632-3640. doi: 10.1002/cncr.30242. Epub 2016 Aug 10.

36.

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer.

Sridharan V, Margalit DN, Lynch SA, Severgnini M, Zhou J, Chau NG, Rabinowits G, Lorch JH, Hammerman PS, Hodi FS, Haddad RI, Tishler RB, Schoenfeld JD.

Br J Cancer. 2016 Jul 12;115(2):252-60. doi: 10.1038/bjc.2016.166. Epub 2016 Jul 5.

37.

Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.

Sridharan V, Gjini E, Liao X, Chau NG, Haddad RI, Severgnini M, Hammerman P, El-Naggar A, Freeman GJ, Hodi FS, Rodig SJ, Dranoff G, Schoenfeld JD.

Cancer Immunol Res. 2016 Aug;4(8):679-87. doi: 10.1158/2326-6066.CIR-16-0031. Epub 2016 Jun 16.

38.

Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon.

Chau NG, Hammerman PS.

Clin Cancer Res. 2016 Aug 1;22(15):3710-2. doi: 10.1158/1078-0432.CCR-16-0582. Epub 2016 Apr 29.

39.

Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.

Ng CY, Yeh YT, Wang CW, Hung SI, Yang CH, Chang YC, Chang WC, Lin YJ, Chang CJ, Su SC, Fan WL, Chen DY, Wu YJ, Tian YC, Hui RC, Chung WH; Taiwan Severe Cutaneous Adverse Reaction Consortium.

J Invest Dermatol. 2016 Jul;136(7):1373-1381. doi: 10.1016/j.jid.2016.02.808. Epub 2016 Mar 18.

40.

Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.

Chau NG, Li YY, Jo VY, Rabinowits G, Lorch JH, Tishler RB, Margalit DN, Schoenfeld JD, Annino DJ, Goguen LA, Thomas T, Becker H, Haddad T, Krane JF, Lindeman NI, Shapiro GI, Haddad RI, Hammerman PS.

Clin Cancer Res. 2016 Jun 15;22(12):2939-49. doi: 10.1158/1078-0432.CCR-15-2314. Epub 2016 Jan 13.

41.

Sequential and Concurrent Chemoradiation: State of the Art.

Chau NG, Haddad RI.

Hematol Oncol Clin North Am. 2015 Dec;29(6):1061-74. doi: 10.1016/j.hoc.2015.07.005. Epub 2015 Oct 21. Review.

PMID:
26568548
42.

Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back.

Chau NG, Lorch JH.

Oncologist. 2015 Jul;20(7):699-701. doi: 10.1634/theoncologist.2014-0476. Epub 2015 Jun 3. No abstract available.

43.

Churg-Strauss syndrome with asymptomatic pulmonary emboli.

Ng CY, Hui RC, Kuo TT, Cheng CY, Wu J.

Indian J Dermatol Venereol Leprol. 2015 Mar-Apr;81(2):201-3. doi: 10.4103/0378-6323.152303. No abstract available.

44.

SF-36 healty survey on psoriasis quality-of-life: a study of 414 Taiwanese patients.

Ng CY, Yang YW, Liu SH, Lu JF, Yang LC, Yang CH, Huang YH.

J Dermatol. 2015 Feb;42(2):159-65. doi: 10.1111/1346-8138.12748. Epub 2015 Jan 13.

PMID:
25583163
45.

Marital status and head and neck cancer outcomes.

Inverso G, Mahal BA, Aizer AA, Donoff RB, Chau NG, Haddad RI.

Cancer. 2015 Apr 15;121(8):1273-8. doi: 10.1002/cncr.29171. Epub 2014 Dec 18.

46.

Feasibility of ablative fractional laser-assisted drug delivery with optical coherence tomography.

Yang CH, Tsai MT, Shen SC, Ng CY, Jung SM.

Biomed Opt Express. 2014 Oct 16;5(11):3949-59. doi: 10.1364/BOE.5.003949. eCollection 2014 Nov 1.

47.

Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options.

Chau NG, Rabinowits G, Haddad RI.

Curr Treat Options Oncol. 2014 Dec;15(4):595-610. doi: 10.1007/s11864-014-0309-1. Review.

PMID:
25240410
48.

Localized bladder amyloidosis mimicking bladder carcinoma.

Ng CY, Huang WH, Huang HC, Wang LJ, Lee SY.

Kidney Int. 2014 May;85(5):1245. doi: 10.1038/ki.2013.312. No abstract available.

49.

Locally advanced head and neck cancer.

Cmelak AJ, Arneson K, Chau NG, Gilbert RW, Haddad RI.

Am Soc Clin Oncol Educ Book. 2013:237-44. doi: 10.1200/EdBook_AM.2013.33.237. Review.

50.

Vandetanib for the treatment of medullary thyroid cancer.

Chau NG, Haddad RI.

Clin Cancer Res. 2013 Feb 1;19(3):524-9. doi: 10.1158/1078-0432.CCR-12-2353. Epub 2012 Dec 11. Review.

Supplemental Content

Loading ...
Support Center